ImmunoCellular Therapeutics Reports Second Quarter Results

Company Ends Quarter with $11.3 million cash and cash equivalents

ImmunoCellular Therapeutics Reports Second Quarter Results

<0> For ImmunoCellular Therapeutics, Ltd.CEOcast, Inc.James Young, 212-732-4300Investor Relations </0>

ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC) (“ImmunoCellular” or the “Company”), today announced second quarter results for the period ended June 30, 2012.

Highlights of the second quarter and recent weeks include:

The Company incurred $3.1 million in the quarter to support research and development activities and for general operations. Net loss for the quarter of approximately $6.5 million, or $0.16 per basic and diluted share, included an expense for the change in fair value of its warrant liabilities of $3.3 million primarily driven by the increase in the Company’s stock price.

ImmunoCellular Therapeutics, Ltd. Chief Executive Officer Manish Singh commented, “We are pleased by the progress in our Phase II clinical trial of ICT-107. We look forward to continuing to work closely with the investigators and trial sites to complete enrollment and to obtaining patient data.”

ImmunoCellular Therapeutics () is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company is currently conducting a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for newly diagnosed glioblastoma. To learn more about IMUC, please visit